Pulse ·

Familial hypercholesterolaemia: why catching it in childhood changes everything

By Dr HB Lo, FACRRM 4 min read
Verdict Yes — worth knowing about

Familial hypercholesterolaemia (FH) affects roughly 1 in 163 people — but most go undiagnosed. A 12-year follow-up of the SAFEHEART study found children with FH who started cholesterol-lowering treatment early had a 0.3% cardiovascular event rate, versus 11.8% in their parents who started treatment decades later.

The difference is cumulative LDL burden: early treatment cut lifetime cholesterol exposure by roughly half. A Bavarian population screening program found FH in 1.1% of over 25,000 children tested. Australia has no equivalent national childhood screening program.

What just happened

A report published today in the Medical Republic brings together two landmark datasets on familial hypercholesterolaemia — and the numbers are striking enough to warrant a proper look.

Familial hypercholesterolaemia is an inherited condition that drives LDL cholesterol to dangerous levels from birth. It is not a lifestyle condition. The gene is there from conception, and so is the cholesterol — loading up on arterial walls during every year the condition goes untreated. FH affects roughly 1 in 163 Australians based on recent genomic population estimates, which would put the affected population at over 160,000 people. Most of them do not know they have it.

The first dataset — the SAFEHEART cohort from Spain — followed 348 children with genetically confirmed heterozygous FH, along with their parents, over a median of 12.4 years from 2004 to 2024. Children started cholesterol-lowering medication at a median age of 14.5 years; their parents had started treatment at a median of 36.1 years — two decades later.

By the end of follow-up, the difference in outcomes was stark. Cardiovascular events occurred in just 0.3% of FH children, compared with 11.8% of FH parents. One non-fatal acute coronary syndrome occurred in a child at age 25.2 — one event, in a cohort of 348 children with a condition that, untreated, reliably causes early heart disease.

Both-and

The number behind the number

That 11.8% vs 0.3% comparison is the headline. But the more instructive figure is the one that explains it: cumulative LDL-C burden.

FH children in SAFEHEART had a median cumulative LDL-C burden of 5,909 mg/dL-years over the follow-up period. Their parents accumulated 10,206 mg/dL-years. That is the difference early treatment makes — not just getting the LDL down, but getting it down before decades of exposure have already been banked.

This is what makes FH different from most cardiovascular risk conversations. We usually talk about LDL in terms of a current reading and a target. FH reframes it as a time-exposure problem. The artery wall does not care about today’s level — it cares about the total dose it has absorbed since birth.

The sex-specific data from SAFEHEART adds another layer worth pausing on. Among parents with FH, male parents experienced cardiovascular events at 21.2% — more than ten times the rate of female parents at 2.1%. This gap may reflect the earlier loss of oestrogen-mediated cardioprotection in men, and it reinforces a common pattern: cardiovascular risk in women presents later, more subtly, and is more easily missed. The women in SAFEHEART were not unaffected — they carried the gene and the LDL load — but their events came later, which can create a false reassurance in clinical conversations.

The screening question

The second dataset is the VRONI program — a population-based cholesterol screening program across Bavaria, Germany, that tested over 25,000 children aged 5 to 15 between 2020 and 2024, enrolling around 36% of regional paediatricians.

Of the children screened, 6.6% exceeded the LDL-C threshold. Of those, genetic testing confirmed FH-causing variants in 17% — representing 1.1% of the total cohort. Prevalence adjusted for ascertainment bias came out at approximately 1 in 163 — consistent with large genomic databases.

The diagnostic yield increased sharply with LDL level: children with LDL above 5.17 mmol/L had a 78.6% probability of carrying an FH variant. Simple fingertip blood sampling without fasting made this feasible at the GP and paediatrician level.

This matters for the Australian context because we have no equivalent program. The European Atherosclerosis Society, the National Lipid Association, and the AAP have all recommended childhood screening for FH. Only Slovenia and Slovakia have operationalised it at a national level. Australia has RACGP guidance supporting cascade screening — identifying relatives of confirmed cases — but no population-level childhood program.

Cascade screening is valuable and underutilised, but it has a logical limit: it requires a known index case. Population screening identifies the cases before the first event. Given that the first presentation of FH in an untreated adult is sometimes a myocardial infarction at 40, the case for catching it earlier than that is not a difficult one to make.

The clinical gap that persists

The practical implication for general practice is that a child presenting to a GP with an LDL above 3.4 mmol/L — even in the absence of a known family history — warrants further assessment for FH. The VRONI data suggests the diagnostic yield at higher LDL thresholds is substantial, and the cost of missing it is measured in decades of arterial exposure.

A family history of premature coronary artery disease — a first-degree relative with a heart attack before age 55 in a man, or 65 in a woman — is the other obvious clinical trigger. Most people with FH do not know the diagnosis. The history may be “grandfather had a heart attack at 52” with no further workup ever done.

My two cents

The 0.3% vs 11.8% figure is the kind of contrast that is easy to understate. In a condition this common, this heritable, and this preventable — once detected — that gap represents a real human cost. Not a statistical abstraction. People who had coronary artery disease they would not have had if the LDL had been treated fifteen or twenty years earlier.

Australia does not need to wait for a national program to act on this. If you have a family history of early heart disease, high cholesterol, or a confirmed FH diagnosis in a relative, it is worth raising with your GP — for yourself, and for children in the family. The test is simple. The treatment is available. The difference it makes, across decades, is in the data.

Verdict: yes — the SAFEHEART data are compelling and the Australian gap in childhood screening is real.

Sources cited

  1. Catching familial hypercholesterolaemia early pays off. Medical Republic, 20 August 2026. https://www.medicalrepublic.com.au/catching-familial-hypercholesterolaemia-early-pays-off/128345

Frequently asked questions

  • How is familial hypercholesterolaemia diagnosed in Australia?

    FH is diagnosed using the Dutch Lipid Clinic Network score or Simon Broome criteria, combining LDL cholesterol level, family history, clinical signs (tendon xanthomata, corneal arcus), and genetic testing. A fasting LDL-C above 5 mmol/L in an adult, or above 3.4 mmol/L in a child, warrants further assessment. Genetic cascade screening — testing first-degree relatives of a confirmed case — is the most efficient way to identify affected family members.

  • What treatments are available for FH in Australia?

    First-line is a high-intensity statin, typically started in childhood once FH is confirmed. Ezetimibe is commonly added if LDL-C targets are not met. PCSK9 inhibitors (evolocumab, alirocumab) are PBS-listed for adults with FH at high cardiovascular risk who cannot reach LDL targets on maximum tolerated statin plus ezetimibe. Lifestyle modification — reduced saturated fat, regular exercise, no smoking — supports but does not replace medication.